Entecavir to guard against hepatitis B return after stem cell transplant
Tests entecavir in past hepatitis B patients undergoing stem cell transplant.
Plain-language title generated from the registry record
Registry title: Prophylactic Entecavir for HBV Reactivation in Past HBV Infected Patients With Hematopoietic Stem Cell Transplantation
Key facts
- Where
- Seoul, South KoreaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 19 and 70 years old?
Source: NCT04942886, who can take part
Where in South Korea
- Jeong Won JangSeoul, South KoreaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Seoul St. Mary's Hospital
- Trial code
- NCT04942886
- Record updated
- 18 July 2025
- Original description
This study is a randomized, prospective, comparative study of the effectiveness of prophylactic entecavir treatment for HBV reactivation in past HBV infected patients (HBsAg-, HBcIgG+) with allogeneic hematopoietic stem cell transplantation.Read full original descriptionShow less
A Randomized, Prospective, Comparative Study of the Effectiveness of Prophylactic Entecavir Treatment for HBV Reactivation in Past HBV Infected Patients With Hematopoietic Stem Cell Transplantation
This study is a randomized, prospective, comparative study of the effectiveness of prophylactic entecavir treatment for HBV reactivation in past HBV infected patients (HBsAg-, HBcIgG+) with allogeneic hematopoietic stem cell transplantation.
Inclusion Criteria:; Age: 19 - 70; Patients receiving allogeneic hematopoietic stem cell transplantation; HBV serologic test: HBsAg (-), anti-HBc IgG (+) before receiving allogeneic hematopoietic stem cell transplantation; ECOG performence: 0-2; patients with informed consent; Exclusion Criteria:; HBV DNA (+, ≥10 IU/mL) at the time of screening; Receiving hematopoietic stem cell transplantation from donor with HBsAg+; Combined other chronic liver disease (severe alcoholics, autoimmune hepatitis, chronic hepatitis C etc.); HIV (+); Previous antiviral therapy history for chronic hepatitis B; Other concomitant malignancy; Combined autoimmune disease (rheumatic arthritis, SLE etc); CTP class B, C; Decompensated complications (ascites, hepatic encephalopathy etc.); Active tuberculosis; Patients with lymphoma; Patients receiving autologous hematopoietic stem cell transplantation.